Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ClouDr Group's Enterprise Value is €12.0 Mil.
ClouDr Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-10.2 Mil. Therefore, ClouDr Group's EV-to-FCF for today is -1.18.
The historical rank and industry rank for ClouDr Group's EV-to-FCF or its related term are showing as below:
FRA:H3L'
s EV-to-FCF Range Over the Past 10 Years
Min: -27.54 Med: -2.09 Max: -0.69
Current: -1.3
During the past 7 years, the highest EV-to-FCF of ClouDr Group was -0.69. The lowest was -27.54. And the median was -2.09.
FRA:H3L's EV-to-FCF is ranked worse than 100% of 68
companies
in the Medical Distribution industry
Industry Median: 17.65
vs FRA:H3L: -1.30
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ClouDr Group's PE Ratio (TTM) for today is calculated as:
ClouDr Group's share price for today is €0.0505.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ClouDr Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.184.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ClouDr Group EV-to-FCF Related Terms
ClouDr Group EV-to-FCF Historical Data
* Premium members only.
The historical data trend for ClouDr Group's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, ClouDr Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClouDr Group EV-to-FCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, ClouDr Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where ClouDr Group's EV-to-FCF falls into.
ClouDr Group's current Enterprise Value is €12.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ClouDr Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-10.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClouDr Group (FRA:H3L) has a EV-to-FCF of -1.18 as of Aug. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ClouDr Group and its competitors. According to the industry distribution chart, ClouDr Group ranks #999999 out of 68 companies in the Medical Distribution industry.
Is ClouDr Group's EV-to-FCF too high?
ClouDr Group's current EV-to-FCF is -1.18. Based on the distribution chart, ClouDr Group ranks #999999 out of 68 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, ClouDr Group has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does ClouDr Group's EV-to-FCF compare to MCK and COR?
According to the Medical Distribution industry distribution chart, ClouDr Group ranks #999999 out of 68 companies for EV-to-FCF. This places ClouDr Group in the lower half of its industry. The industry median EV-to-FCF is 17.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Distribution company?
The median EV-to-FCF among Medical Distribution companies is 17.65, based on 68 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ClouDr Group and its competitors. For the Medical Distribution industry, the median EV-to-FCF is 17.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ClouDr Group's current EV-to-FCF is -1.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClouDr Group stock overvalued right now?
ClouDr Group (FRA:H3L) has a current EV-to-FCF of -1.18. The stock's GF Value™ is €0.08, compared to a current price of €0.05 — trading 36.9% below its estimated fair value. The current EV-to-FCF is -1.18. ClouDr Group's overall GF Score™ is 48/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For ClouDr Group (FRA:H3L), the current EV-to-FCF is -1.18 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ClouDr Group (FRA:H3L) Overvalued in 2026?
Based on GuruFocus' analysis, ClouDr Group stock appears to be undervalued.
The current stock price of €0.05 is trading 36.9% below its estimated GF Value™ of €0.08.
Key valuation signals for FRA:H3L:
EV-to-FCF: -1.18
GF Value™: €0.08 vs. price of €0.05 (36.9% below fair value)
No single metric tells the full story. See the FRA:H3L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. The company's in-hospital solution consists of sales of medical devices, consumables, and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies, and the out-of-hospital solution connects doctors and patients, and provides high-quality and trustworthy medical services through the AI vertical model ClouD GPT. The company generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
48GF Score
Get the complete analysis for FRA:H3L
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:H3L has been successfully added to your 
